



7600 Terrace Avenue, Suite 203 • Middleton, WI 53562-3174

TEL: (608) 836-3787 • FAX: (608) 831-5485 • E-MAIL: srnt@tmahq.com • WEBSITE: www.srnt.org

OFFICERS

- Kenneth A. Perkins, PhD
President
- William Corrigan, PhD
Past-President
- Harry Lando, PhD
President-Elect
- Raymond Niaura, PhD
Secretary-Treasurer
- David Balfour, PhD
Rachel Tyndale, PhD
Member Delegates

COUNCILS

- Ann McNeill, PhD
Chair, Membership & Development Council
- Leslie Schuh, PhD
Membership Committee
- Mitchell A. Nides, PhD
Development Committee
- Joy M. Schmitz, PhD
Chair, Program & Training Council
- Thomas Eissenberg, PhD
2002 Program Committee
- Janine Pillitteri, PhD
Training Committee

- David Abrams, PhD
Chair, Publications & Communications Council
- Gary Swan, PhD
NTR Editor
- Judith Gordon, PhD
Newsletter Committee
- Richard Brown, PhD
Communications Committee

- Maxine L. Stitzer, PhD
Chair, Scientific Liaison & Public Policy Council
- Marina R. Picciotto, PhD
Scientific Liaison Committee
- John Hughes, MD
Public Policy Committee

COMMITTEES

- Maxine L. Stitzer, PhD
Awards
- Marcia M. Ward, PhD
Finance
- William Corrigan, PhD
Long Range Planning
- Ovide Pomerleau, PhD
Global Network
- Jasjit Ahluwalia, MD
Nominations
- Linda Pederson, PhD
Special Populations

EXECUTIVE STAFF

- Elizabeth A. Klipping
Executive Director

April 23, 2002

Rec'd
5/31/02

Lester M. Crawford, Jr., D.V.M., Ph.D.
Deputy Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. Crawford,

The Society for Research on Nicotine and Tobacco (SRNT) petitions the Food and Drug Administration (FDA) to regulate Ariva tobacco lozenges. We are also submitting similar petitions on Omni and Advance cigarettes and Nicotine Water. In addition, we have attached two similar petition we sent to the agency on Eclipse. We are disappointed that no apparent action has been taken regarding Eclipse.

SRNT (www.srnt.org) is composed of over 600 of the leading scientists researching nicotine and tobacco issues in the US and 33 other countries. Many of our members have served on WHO, FDA and other governmental/public organizational committees. One of SRNT's major missions is to provide scientific information and advice to policy makers.

Our reasons for urging the FDA to regulate Ariva are similar to those outlined in our Eclipse petition and include the following:

- Traditional cigarettes are known toxic nicotine delivery products that are widely available and cause a huge amount of harm. Thus, we would reiterate the continuing and urgent need for FDA to regulate traditional cigarettes
- The current scientific database suggests it is feasible to develop tobacco products that are less toxic than current cigarettes. As the Institute of Medicine concluded, under the appropriate conditions, such products could reduce the risk of tobacco use.
- Ariva advertising either explicitly or implicitly states Ariva is a smokeless tobacco product and smokeless tobacco is less harmful than smoked tobacco.¹ Although the latter may be true, we are unaware of a comprehensive scientific analysis of the magnitude of this risk reduction, how much risk remains in using smokeless tobacco and the comparative risk in using smokeless vs nicotine replacement therapies.² The recent Institute of Medicine report stated such information is necessary to allow promotion of smokeless as a substitute for cigarettes and outlined the types of research that would need to be done to allow such promotion.

02P.0205

CP1

OFFICERS

Kenneth A. Perkins, PhD
President
 William Corrigan, PhD
Past-President
 Harry Lando, PhD
President-Elect
 Raymond Niaura, PhD
Secretary-Treasurer
 David Balfour, PhD
 Rachel Tyndale, PhD
Member Delegates

COUNCILS

Ann McNeill, PhD
Chair, Membership & Development Council
 Leslie Schuh, PhD
Membership Committee
 Mitchell A. Nides, PhD
Development Committee

Joy M. Schmitz, PhD
Chair, Program & Training Council

Thomas Eisenberg, PhD
2002 Program Committee
 Janine Pillitteri, PhD
Training Committee

David Abrams, PhD
Chair, Publications & Communications Council

Gary Swan, PhD
NTR Editor
 Judith Gordon, PhD
Newsletter Committee
 Richard Brown, PhD
Communications Committee

Maxine L. Stitzer, PhD
Chair, Scientific Liaison & Public Policy Council

Marina R. Picciotto, PhD
Scientific Liaison Committee
 John Hughes, MD
Public Policy Committee

COMMITTEES

Maxine L. Stitzer, PhD
Awards

Marcia M. Ward, PhD
Finance

William Corrigan, PhD
Long Range Planning

Ovide Pomerleau, PhD
Global Network

Jasjit Ahluwalia, MD
Nominations

Linda Pederson, PhD
Special Populations

EXECUTIVE STAFF

Elizabeth A. Klipping
Executive Director

- Also implicit in Ariva advertising (e.g. "for use in situations in which smoking is not allowed") is that the product would mitigate withdrawal symptoms and craving. We are unaware of any data to support this implication.
- Such an analysis is important because smokers do believe and often overestimate health claims made by the tobacco industry. For example, a recent NCI Monograph³ concluded that most smokers believe low tar/nicotine cigarettes are safer even though these products make only vague implicit health claims in their advertising. The NCI report also concluded the health benefits of low tar/nicotine cigarettes are either non-existent or very small.³ Finally, recent scientific^{4,5} and industry documents⁶ suggest the marketing of low tar/low nicotine cigarettes has undermined many smokers intentions to stop smoking. We fear the same may be true for Ariva
- Ariva uses a tobacco stated to have fewer carcinogens than regular tobacco.¹ However, this claim has not been verified. A recent Institute of Medicine report has outlined the types of evidence necessary to permit a claim of reduced risk.⁷ For example, relying on machine-testing data alone is problematic because experience with low tar/nicotine cigarettes clearly shows that machines testing can be subverted and its results are not generalizable to human smoking.³ To our knowledge, there are no published studies of carcinogen exposure in humans using the tobacco in Ariva.
- New products can produce unexpected new risks. For example, light cigarettes increase adenocarcinoma of the lung³ and Eclipse increases carbon monoxide (CO) levels⁸ and produces inhalation of fiber glass particles;⁹ a comprehensive analysis of any risks by Ariva is needed.
- It is unclear how Ariva will be used. If smokers use Ariva as advertised; i.e., to avoid smoking restrictions, they may simply add Ariva exposure to their ongoing daily consumption of cigarettes. If this were true, Ariva would actually increase risk for smokers.
- The availability of Ariva along with implicit or explicit claims of it being safer than cigarettes might increase initiation of smoking or undermine motivation for stopping smoking.⁷ The Institute of Medicine report also raised this concern.



7600 Terrace Avenue, Suite 203 • Middleton, WI 53562-3174
TEL: (608) 836-3787 • FAX: (608) 831-5485 • E-MAIL: srnt@tmahq.com • WEBSITE: www.srnt.org

OFFICERS

Kenneth A. Perkins, PhD
President
William Corrigan, PhD
Past-President
Harry Lando, PhD
President-Elect
Raymond Niaura, PhD
Secretary-Treasurer
David Balfour, PhD
Rachel Tyndale, PhD
Member Delegates

COUNCILS

Ann McNeill, PhD
Chair, Membership & Development Council
Leslie Schuh, PhD
Membership Committee
Mitchell A. Nides, PhD
Development Committee

Joy M. Schmitz, PhD
Chair, Program & Training Council

Thomas Eissenberg, PhD
2002 Program Committee
Janine Pillitteri, PhD
Training Committee

David Abrams, PhD
Chair, Publications & Communications Council

Gary Swan, PhD
NTR Editor
Judith Gordon, PhD
Newsletter Committee
Richard Brown, PhD
Communications Committee

Maxine L. Stitzer, PhD
Chair, Scientific Liaison & Public Policy Council

Marina R. Picciotto, PhD
Scientific Liaison Committee
John Hughes, MD
Public Policy Committee

COMMITTEES

Maxine L. Stitzer, PhD
Awards

Marcia M. Ward, PhD
Finance

William Corrigan, PhD
Long Range Planning

Ovide Pomerleau, PhD
Global Network

Jasjit Ahluwalia, MD
Nominations

Linda Pederson, PhD
Special Populations

EXECUTIVE STAFF

Elizabeth A. Klipping
Executive Director

In summary, SRNT believes there are many unanswered questions about the impact of Ariva on public health. Thus, SRNT urges the FDA to institute regulatory procedures to require sufficient study of Ariva so that the policy mistakes that were made with low-tar/low-nicotine cigarettes^{3,7} are not repeated.

Sincerely,

John R. Hughes, M.D.
Chair, Policy Committee
SRNT

cc: SRNT Executive Committee
SRNT Policy Committee



7600 Terrace Avenue, Suite 203 • Middleton, WI 53562-3174
TEL: (608) 836-3787 • FAX: (608) 831-5485 • E-MAIL: srnt@tmahq.com • WEBSITE: www.srnt.org

OFFICERS

Kenneth A. Perkins, PhD
President
William Corrigan, PhD
Past-President
Harry Lando, PhD
President-Elect
Raymond Niaura, PhD
Secretary-Treasurer
David Balfour, PhD
Rachel Tyndale, PhD
Member Delegates

COUNCILS

Ann McNeill, PhD
Chair, Membership & Development Council
Leslie Schuh, PhD
Membership Committee
Mitchell A. Nides, PhD
Development Committee

Joy M. Schmitz, PhD
Chair, Program & Training Council
Thomas Eissenberg, PhD
2002 Program Committee
Janine Pillitteri, PhD
Training Committee

David Abrams, PhD
Chair, Publications & Communications Council
Gary Swan, PhD
NTR Editor
Judith Gordon, PhD
Newsletter Committee
Richard Brown, PhD
Communications Committee

Maxine L. Stitzer, PhD
Chair, Scientific Liaison & Public Policy Council
Marina R. Picciotto, PhD
Scientific Liaison Committee
John Hughes, MD
Public Policy Committee

COMMITTEES

Maxine L. Stitzer, PhD
Awards
Marcia M. Ward, PhD
Finance
William Corrigan, PhD
Long Range Planning
Ovide Pomerleau, PhD
Global Network
Jasjit Ahluwalia, MD
Nominations
Linda Pederson, PhD
Special Populations

EXECUTIVE STAFF

Elizabeth A. Klipping
Executive Director

Reference List

1. Fairclough, G. 'Cigarette' mints target customers who want alternative to cigarettes. 4-27-2001 Wall Street J
2. Henningfield JE, Fagerstrom K-O. Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress? Tob Control. 2002;253-257.
3. National Institutes of Health. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph 13, Rockville, MD: National Cancer Institute, 2001.
4. Hughes JR. Do light cigarettes undermine cessation? Tob Control. 2001;10:41-43.
5. Giovino GA, Tomar SI, Reddy MN, et al. Attitudes, knowledge, and beliefs about low-yield cigarettes among adolescents and adults, In: The NCI Expert Committee, ed. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes. Smoking and Tobacco Control Monograph 7. Bethesda, MD:National Cancer Institute; 1996:39-57.
6. Glantz S. The Cigarette Papers, Berkeley, CA: University of California Press, 1996.
7. Institute of Medicine. Clearing the Smoke. Assessing the Science Base for Tobacco Harm Reduction, Washington, DC: National Academy Press, 2001.
8. Fagerstrom K-O, Hughes JR, Callas PW. Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine Tob Res, in press.



7600 Terrace Avenue, Suite 203 • Middleton, WI 53562-3174
TEL: (608) 836-3787 • FAX: (608) 831-5485 • E-MAIL: srnt@tmahq.com • WEBSITE: www.srnt.org

OFFICERS

Kenneth A. Perkins, PhD
President
William Corrigan, PhD
Past-President
Harry Lando, PhD
President-Elect
Raymond Niaura, PhD
Secretary-Treasurer
David Balfour, PhD
Rachel Tyndale, PhD
Member Delegates

COUNCILS

Ann McNeill, PhD
Chair, Membership & Development Council
Leslie Schuh, PhD
Membership Committee
Mitchell A. Nides, PhD
Development Committee

Joy M. Schmitz, PhD
Chair, Program & Training Council
Thomas Eissenberg, PhD
2002 Program Committee
Janine Pillitteri, PhD
Training Committee

David Abrams, PhD
Chair, Publications & Communications Council
Gary Swan, PhD
NTR Editor
Judith Gordon, PhD
Newsletter Committee
Richard Brown, PhD
Communications Committee

Maxine L. Stitzer, PhD
Chair, Scientific Liaison & Public Policy Council
Marina R. Picciotto, PhD
Scientific Liaison Committee
John Hughes, MD
Public Policy Committee

COMMITTEES

Maxine L. Stitzer, PhD
Awards
Marcia M. Ward, PhD
Finance
William Corrigan, PhD
Long Range Planning
Ovide Pomerleau, PhD
Global Network
Jasjit Ahluwalia, MD
Nominations
Linda Pederson, PhD
Special Populations

EXECUTIVE STAFF

Elizabeth A. Klipping
Executive Director

9. Pauly JL, Lee HJ, Hurley EL, Cumming KM, Lesses JD, Streck RJ. Glass fiber contamination of cigarette filters: An additional health risk to the smoker? Cancer Epidemiol Biomarkers Prev. 1998;7:967-979.



#53

7600 Terrace Avenue, Suite 203 • Middleton, WI 53562-3174

TEL: (608) 836-3787 • FAX: (608) 831-5485 • E-MAIL: srnt@tmahq.com • WEBSITE: www.srnt.org

March 19, 2001

OFFICERS

- William Corrigan, PhD
President
- Dorothy Hatsuakami, PhD
Past-President
- Kenneth Perkins, PhD
President-Elect
- Raymond Hiaura, PhD
Secretary-Treasurer
- David Balfour, PhD
- Judith O'Keefe, PhD
- Nancy Iligotti, MD
- Rachel Tyndale, PhD
Member Delegates

Bernard A. Schwetz, D.V.M., Ph.D.
Acting Principal Deputy Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. Schwetz,

COUNCILS

- Ann McNeill, PhD
Chair, Membership & Development
- Leslie Schuh, PhD
Membership Committee
- Mitchell Hides, PhD
Development Committee
- Joy Schmitz, PhD
Chair, Program & Training
- Thomas Eissenberg, PhD
- David Vietter, PhD
2001 Program
- Janine Pitteri, PhD
Training Committee
- Ovide F. Pomeleau, PhD
Chair, Publications & Communications
- Janet Brigham, PhD
Newsletter Committee
- (open)
Communications Committee
- Gary Iwan, PhD
STR Editor
- Richard Brown, PhD
Website Committee
- Maxine Sitzer, PhD
Chair, Scientific Liaison & Public Policy
- Kenneth Perkins, PhD
Scientific Liaison Committee
- John Hughes, MD
Public Policy Committee

The Society for Research on Nicotine and Tobacco would again suggest to the FDA the need for and urgency to regulate Eclipse and other products that claim or infer to reduce exposure to tobacco toxins. Enclosed is a copy of our prior letter to former FDA Commissioner Henney on this matter.

We are reiterating this request for two reasons. First, the recent findings of the National Academy of Science's Institute of Medicine report, "Clearing the Smoke." This report summarized research around Eclipse and Eclipse-like products and concluded that such products "have not yet been evaluated comprehensively enough . . . to provide a scientific basis for concluding they are associated with a reduced risk of disease" and "the net impact on the health of the population as a whole [of Eclipse-like products] could, in fact, be negative."

Second, recent scientific findings suggest Eclipse might present a new harm via exposure to glass fibers from Eclipse. Yet RJR has not warned consumers of this.

Third, since we last wrote even more reduced risk products have been either marketed or are in development. First, RJR has expanded their market to direct-to-consumer sales in 1700 retail outlets in the Dallas-Ft Worth area. Star Scientific has marketed a new cigarette it claims has reduced carcinogens "Vantage", Philip Morris has introduced a "reduced smoke" product (Accord) and Brown and Williamson and Vector Group are developing reduced risk cigarettes. All this activity in the last few months clearly indicates, that this issue will not go away and that FDA urgently needs to take a stand about regulation of these products before its credibility is seriously questioned.

Sincerely

John R. Hughes, M.D.
Chair, Policy Committee, SRNT

COMMITTEES

- Maxine Sitzer, PhD
Awards
- Marcia Ward, PhD
Finance
- Dorothy Hatsuakami, PhD
Long Range Planning
- Kari Fagerstrom, PhD
Global Network
- Jasjit Ahluwalia, MD
Nominations
- Edward Singleton, PhD
Special Populations

EXECUTIVE STAFF

- Elizabeth A. Klipping
Executive Director

**SOCIETY for
RESEARCH on
NICOTINE and
TOBACCO**

7611 Elmwood Avenue, Suite 202 • Middleton, WI 53562

TEL: 608-836-3787 • FAX: 608-831-5485 • E-MAIL: srnt1@aol.com • WEB SITE: www.srnt.org

OFFICERS

Dorothy Hatsukami, PhD
President

Jack E. Henningfield, PhD
Past-President

Harry A. Lindo, PhD
Secretary-Treasurer

Karl Fagerstrom, PhD
Judith Ockene, PhD
Members Delegates

COUNCILS

Scott Leischow, PhD
*Chair, Membership
& Development*

Lisa Briener, PhD
Membership Committee

Mitchell Lindes, PhD
Development Committee

Stephen Heishman, PhD
Chair, Program Training

David Witter, PhD
2000 Program

Janine Pittler, PhD
Training Committee

Ovide F. Pomeroy, PhD
*Chair, Publications
& Communications*

Janet Brigham, PhD
Newsletter Committee

Ted Klein, MA
Communications Committee

Gary Swan, PhD
Letter Editor

Richard Brown, PhD
Website Committee

Maxine Stitzer, PhD
*Chair, Scientific Liaison &
Public Policy*

Kenneth Killar, PhD
Scientific Liaison Committee

John Hughes, MD
Public Policy Committee

COMMITTEES

Raymond Niaura, PhD
Finance

Jack Henningfield, PhD
Long Range Planning

Karl Fagerstrom, PhD
Global Network

Jasjit Ahluwalia, MD
Nominations

Edward Singleton, PhD
Minority Populations

STAFF

Sarah E. Evans
Executive Director

June 16, 2000

Jane Henney, M.D.
Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Re: Regulation of Eclipse

Dear Dr. Henney,

The Society for Research on Nicotine and Tobacco (SRNT) urges The Food and Drug Administration to review the health claims RJ Reynolds is making for their Eclipse product. We believe there is insufficient and contrary scientific results to support these claims and thus FDA should institute some form of regulatory procedures over Eclipse.

Our society consists of 600+ of the leading scientists in tobacco and nicotine research in the US and 33 other countries; thus, SRNT is the largest repository of scientific information in the world. One of SRNT's major missions is to provide scientific data and advise to policy makers.

Our reasons for urging FDA to review Eclipse health claims are as follows:

- Smokers do believe and often overestimate health claims made by the tobacco industry. For example, a recent NCI/ Presidential Commission report¹ (and other studies²) concluded that most smokers believe low tar/nicotine cigarettes are safer even though these products make only vague implicit health claims in their advertising. The NCI report (and other reports³) also conclude the health benefits of low tar/nicotine cigarettes are either non-existent or very small. Finally, recent scientific^{2,4} and industry documents⁵ suggest the marketing of low tar/low nicotine cigarettes has undermined many smokers intentions to stop smoking.
- Although there are data that Eclipse delivers fewer carcinogens than regular cigarettes,⁶⁻¹⁰ there are problems with these data. For example, machine-testing data⁶⁻⁸ must be interpreted cautiously because experience with low tar/nicotine cigarettes clearly shows that people do not smoke like machines do.³ To our knowledge, there are only two published studies of carcinogen exposure in

**SOCIETY for
RESEARCH on
NICOTINE and
TOBACCO**

7611 Elmwood Avenue, Suite 202 - Middleton, WI 53562

TEL: 608-836-3787 • FAX: 608-831-5485 • E-MAIL: srnt1@aol.com • WEB SITE: www.srnt.org

humans using Eclipse.^{9:10} These studies used small samples, short durations of exposure and were conducted by the tobacco industry.

OFFICERS

Dorothy Hat: Jakani, PhD
President
Jack E. Henningfield, PhD
Past-President
Harry A. Lando, PhD
Secretary-Treasurer
Karl Fagerstrom, PhD
Judith Ockene, PhD
Member Delegates

COUNCILS

Scott Leischow, PhD
Chair, Membership
& Development
Lisa E Bauer, PhD
Membership Committee
Mitchell Hides, PhD
Development Committee
Stephen Heistman, PhD
Chair, Program & Training
David Watter, PhD
2007 Program
Janine Pilleri, PhD
Training Committee
Ovide F. Pomeau, PhD
Chair, Publications
& Communications
Janet Brigham, PhD
Newsletter Committee
Ted Klein, MA
Communications Committee
Gary Sivan, PhD
Web Editor
Richard Brown, PhD
Website Committee
Maxine Stitzer, PhD
Chair, Scientific Liaison &
Public Policy
Kenneth Killar, PhD
Scientific Liaison Committee
John Hughes, MD
Public Policy Committee

COMMITTEES

Raymond Niaura, PhD
Finance
Jack Henningfield, PhD
Long Range Planning
Karl Fagerstrom, PhD
Global Network
Jasjit Ahluwalia, MD
Nominations
Edward Singletton, PhD
Minority Populations


STAFF

Sarah L. Evans
Executive Director

- Both an independent study¹¹ and an industry study¹² found that use of Eclipse increased carbon monoxide (CO) levels compared to smoking traditional cigarettes. This is important as increased CO is linked to cardiovascular disease¹³ and smokers are more likely to die of tobacco-induced cardiovascular diseases than of tobacco-induced cancers¹⁴.
- Eclipse exposes smokers to inhalation of fiber glass particles;¹⁵ thus, Eclipse may add a new risk of cancer and lung diseases.
- It is unclear how Eclipse will be used. The only study of the use pattern of Eclipse did not present Eclipse in the manner that RJR is pursuing.¹¹ Smokers might substitute Eclipse for cigarettes. On the other hand, they might use Eclipse solely to avoid smoking restrictions and just add Eclipse use to their ongoing daily consumption of cigarettes. If the later is true, Eclipse could actually increase risk.
- The availability of Eclipse along with claims of it being a safer cigarette might increase initiation of smoking or would undermine motivation for stopping smoking. Although an initial study suggests that Eclipse does not undermine motivation to quit,¹¹ this study lacked an adequate control group to clearly answer the question.

In summary, SRNT believes there are many unanswered questions about the validity of the health claims made by Eclipse.^{16:17} In fact, we believe the availability of Eclipse could result in a net worsening of public health due to increased CO levels, glass inhalation, higher rates of initiation of smoking, or lower rates of cessation of smoking. In addition, other cigarette substitutes (e.g. Accord) and "safer tobacco" products (e.g. Star Tobacco) are likely to make health claims in the not too distant future. Thus, SRNT urges the FDA to institute regulatory procedures to require sufficient study of Eclipse so that the policy mistakes that were made with low-tar/low-nicotine cigarettes are not repeated with Eclipse and other smoking products making health claims.

Sincerely,


John R. Hughes, M.D.
Chair, Policy Committee
SRNT

cc: Geoff Mumford
Judy Wilkenfeld
SRNT Office
Bill Corrigan

6th Annual Meeting - February 18-20, 2000 - Crystal Gateway Marriott - Arlington, Virginia

**SOCIETY for
RESEARCH on
NICOTINE and
TOBACCO**

7611 Elmwood Avenue, Suite 202 • Middleton, WI 53562
TEL: 608-836-3787 • FAX: 608-831-5485 • E-MAIL: srnt1@aol.com • WEB SITE: www.srnt.org

OFFICERS

Dorothy Hatsukami, PhD
President

Jack E. Henningfield, PhD
Past-President

Harry A. Lando, PhD
Secretary-Treasurer

Karl Fagerstrom, PhD
Judith O'Keefe, PhD
Member Delegates

COUNCILS

Scott Leis'how, PhD
*Chair, Membership
& Development*

Lisa Bauer, PhD
Membership Committee

Mitchell Hides, PhD
Development Committee

Stephen Heishnan, PhD
Chair, Program & Training

David Witter, PhD
2000 Program

Janine Pillitteri, PhD
Training Committee

Ovide F. Pomeroy, PhD
*Chair, Publications
& Communications*

Janet Brigham, PhD
Newsletter Committee

Ted Klein, MA
Communications Committee

Gary Swan, PhD
AFR Editor

Richard Brown, PhD
Website Committee

Maxine Stiller, PhD
*Chair, Scientific Liaison &
Public Policy*

Kenneth Keeler, PhD
Scientific Liaison Committee

John Hughes, MD
Public Policy Committee

COMMITTEES

Raymond Niaura, PhD
Finance

Jack Henningfield, PhD
Long Range Planning

Karl Fagerstrom, PhD
Global Network

Jasjit Ahluwalia, MD
Nominations

Edward Singleton, PhD
Minority Populations

STAFF

Sarah E. Evans
Executive Director

Reference List

1. National Cancer Institute Expert Committee. The FTC Cigarette Test Method for Determining Tar, Nicotine and Carbon Monoxide Yields of US Cigarettes. Smoking and Tobacco Control Monograph #7, Bethesda, MD: National Cancer Institute, 1996.
2. Kozlowski LT, Goldberg ME, Yost BA, White EL, Sweeney CT, Pillitteri JL. Smokers' misperceptions of light and ultra-light cigarettes may keep them smoking. Am J Prev Med. 1998;15:9-16.
3. Nicotine Addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians, Sudbury, Suffolk: The Lavenham Press Ltd., 2000.
4. Giovino GA, Tomar SI, Reddy MN, et al. Attitudes, knowledge, and beliefs about low-yield cigarettes among adolescents and adults. In: The NCI Expert Committee, The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes. Smoking and Tobacco Control Monograph 7. Bethesda, MD: National Cancer Institute; 1996:39-57.
5. Glantz S. The Cigarette Papers, Berkeley, CA: University of California Press, 1996.
6. Borgerding MF, Bodnar JA, Chung HL, et al. Chemical and biological studies of a new cigarette that primarily heats tobacco. Part 1. Chemical composition of mainstream smoke. Food Chem Toxicol. 1997;36:169-182.
7. Bombick BR, Murli H, Avalos JT, et al. Chemical and biological studies of a new cigarette that primarily heats tobacco. Part 2. In vitro toxicology of mainstream smoke condensate. Food Chem Toxicol. 1997;36:183-190.
8. Bombick DW, Ayres PH, Putnam K, Bombick BR, Doolittle DJ. Chemical and biological studies of a new cigarette that primarily heats tobacco. Part 3. In vitro toxicity of whole smoke. Food Chem Toxicol. 1998;36:191-197.
9. deBethizy JD, Borgerding MF, Doolittle DJ, et al. Chemical and biological studies of a cigarette that heats rather than burns tobacco. J Clin Pharmacol. 1990;30:755-763.

**SOCIETY for
RESEARCH on
NICOTINE and
TOBACCO**

7611 Elmwood Avenue, Suite 202 • Middleton, WI 53562

TEL: 608-836-3787 • FAX: 608-831-5485 • E-MAIL: srnt1@aol.com • WEB SITE: www.srnt.org

OFFICERS

Dorothy Hatsukami, PhD
President

Jack E. Henningfield, PhD
Past-President

Harry A. Lando, PhD
Secretary-Treasurer

Karl Fagerstrom, PhD
Judith O. Kene, PhD
Member Delegates

COUNCILS

Scott Leishtow, PhD
Chair, Membership
& Development

Lisa Bauer, PhD
Membership Committee

Mitchell Lides, PhD
Development Committee

Stephen Heishman, PhD
Chair, Program & Training

David Wotter, PhD
2001 Program

Janine Pillitteri, PhD
Training Committee

Ovide F. Pomeroy, PhD
Chair, Publications
& Communications

Janet Brigham, PhD
Newsletter Committee

Ted Klein, MA
Communications Committee

Gary Swan, PhD
MTR Editor

Richard Brown, PhD
Website Committee

Maxine Slieter, PhD
Chair, Scientific Liaison &
Public Policy

Kenneth Keeler, PhD
Scientific Liaison Committee

John Hughes, MD
Public Policy Committee

COMMITTEES

Raymond Nalwa, PhD
Finance

Jack Henningfield, PhD
Long Range Planning

Karl Fagerstrom, PhD
Global Network

Jasjit Anilwalia, MD
Nominations

Edward Singleton, PhD
Minority Populations

STAFF

Sarah E. Evans
Executive Director

10. Smith CJ, McKarns SC, Davis RA, et al. Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutation Research. 1996;361:1-9.
11. Fagerstrom KO, Hughes JR, Rasmussen T, Callas P. The effect of Eclipse on smoking, carbon monoxide and motivation to quit. Nicotine Tobacco Research, in press.
12. Stiles, M. F., Davis, R. A., and Guy, T. D. Human smoking behavior study: Eclipse cigarette compared to usual brand and a new prototype Presented at the 51st Tobacco Chemists' Research Conference, Winston-Salem, NC, Sept. 15, 1997
13. US Dept Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the U.S. Surgeon General, Rockville, MD: U.S. Dept. of Health and Human Services, 1989.
14. Wald N, Howard S, Smith PG, Kjeldsen K. Association between atherosclerotic diseases and carboxyhaemoglobin levels in tobacco smokers. Br Med J. 1973;1:761-765.
15. Pauly JL, Lee HJ, Hurley EL, Cumming KM, Lesses JD, Streck RJ. Glass fiber contamination of cigarette filters: An additional health risk to the smoker? Cancer Epidemiol Biomarkers Prev. 1998;7:967-979.
16. Warner KE, Slade J, Sweanor DT. The emerging market for long-term nicotine maintenance. JAMA. 1997;278:1087-1092.
17. Pauly JL, Streck RJ, Cummings KM. US patents shed light on Eclipse and future cigarettes. Tobacco Ctrl. 1995;4:261-265.